ATE481402T1 - Pyrazolopyridin-derivate - Google Patents

Pyrazolopyridin-derivate

Info

Publication number
ATE481402T1
ATE481402T1 AT04715268T AT04715268T ATE481402T1 AT E481402 T1 ATE481402 T1 AT E481402T1 AT 04715268 T AT04715268 T AT 04715268T AT 04715268 T AT04715268 T AT 04715268T AT E481402 T1 ATE481402 T1 AT E481402T1
Authority
AT
Austria
Prior art keywords
pyrazolopyridine derivatives
pyrazolopyridine
derivatives
Prior art date
Application number
AT04715268T
Other languages
English (en)
Inventor
Rosales Carmen Almansa
Bernado Marina Virgili
Original Assignee
Palau Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32930978&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE481402(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from ES200300640A external-priority patent/ES2214150B1/es
Priority claimed from ES200300727A external-priority patent/ES2214976B1/es
Application filed by Palau Pharma Sa filed Critical Palau Pharma Sa
Application granted granted Critical
Publication of ATE481402T1 publication Critical patent/ATE481402T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT04715268T 2003-02-27 2004-02-27 Pyrazolopyridin-derivate ATE481402T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
ES200300640A ES2214150B1 (es) 2003-02-27 2003-02-27 "nuevos derivados de pirazolopiridinas".
ES200300727A ES2214976B1 (es) 2003-03-14 2003-03-14 "nuevos derivados de pirazolopiridinas".
ES200302504 2003-10-27
PCT/EP2004/001974 WO2004076450A1 (en) 2003-02-27 2004-02-27 Pyrazolopyridine derivates

Publications (1)

Publication Number Publication Date
ATE481402T1 true ATE481402T1 (de) 2010-10-15

Family

ID=32930978

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04715268T ATE481402T1 (de) 2003-02-27 2004-02-27 Pyrazolopyridin-derivate

Country Status (29)

Country Link
US (3) US7468376B2 (de)
EP (1) EP1611131B1 (de)
JP (1) JP4814783B2 (de)
KR (1) KR101312736B1 (de)
AR (1) AR043416A1 (de)
AT (1) ATE481402T1 (de)
AU (1) AU2004215644B2 (de)
BR (1) BRPI0407811A (de)
CA (1) CA2515197C (de)
CL (1) CL2004000398A1 (de)
CY (1) CY1111544T1 (de)
DE (1) DE602004029145D1 (de)
DK (1) DK1611131T3 (de)
EC (2) ECSP056041A (de)
HR (1) HRP20050682B1 (de)
IL (1) IL196021A (de)
IS (1) IS2875B (de)
MX (1) MXPA05009069A (de)
NO (1) NO331917B1 (de)
NZ (1) NZ541836A (de)
PE (1) PE20050521A1 (de)
PL (1) PL378296A1 (de)
PT (1) PT1611131E (de)
RS (1) RS51768B (de)
RU (1) RU2359971C2 (de)
SI (1) SI1611131T1 (de)
TW (1) TWI325865B (de)
UA (1) UA81453C2 (de)
WO (1) WO2004076450A1 (de)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101312736B1 (ko) * 2003-02-27 2013-09-27 팔라우 파르마 에스에이 피라졸로피리딘 유도체
ES2241496B1 (es) * 2004-04-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridina.
TW200618800A (en) * 2004-08-03 2006-06-16 Uriach Y Compania S A J Heterocyclic compounds
GB0427604D0 (en) * 2004-12-16 2005-01-19 Novartis Ag Organic compounds
PE20061119A1 (es) * 2005-01-19 2006-11-27 Aventis Pharma Sa PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie
FR2880891B1 (fr) * 2005-01-19 2007-02-23 Aventis Pharma Sa Pyrazolo pyridines substituees, compositions les contenant, procede de fabrication et utilisation
AU2006264170A1 (en) * 2005-06-27 2007-01-04 Ambrilia Biopharma Inc. Pyrazolo[3,4-b]pyridin-2-yl)-benzoic acid derivatives as HIV integrase inhibitors
EP1899333B1 (de) 2005-06-27 2009-02-18 Sanofi-Aventis Pyrazolopyridinderivate als inhibitoren der kinase 1 des beta-adrenergen rezeptors
ES2270715B1 (es) 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.
FR2889526B1 (fr) 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
AU2006283592A1 (en) 2005-08-22 2007-03-01 Amgen Inc. Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators
AU2006283940A1 (en) * 2005-08-25 2007-03-01 F. Hoffmann-La Roche Ag P38 MAP kinase inhibitors and methods for using the same
MX2008002383A (es) * 2005-08-25 2008-03-18 Hoffmann La Roche Pirazol fusionado como inhibidores de proteinas cinasas activadas por mitogenos p38.
WO2007028129A1 (en) * 2005-09-02 2007-03-08 Pfizer Inc. Hydroxy substituted 1h-imidazopyridines and methods
ES2274712B1 (es) 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
EP2514751A1 (de) 2005-11-15 2012-10-24 Vertex Pharmaceuticals, Inc. Als Kinase-Hemmer verwendbare Azaindazole
KR20090088962A (ko) * 2006-12-15 2009-08-20 바이엘 쉐링 파마 악티엔게젤샤프트 ３-ｈ-피라졸로피리딘 및 그의 염, 이를 포함하는 제약 조성물, 이의 제조 방법 및 이의 용도
EP1932845A1 (de) * 2006-12-15 2008-06-18 Bayer Schering Pharma Aktiengesellschaft 3-H-Pyrazolopyridine und Salze davon, diese enthaltende pharmazeutische Zusammensetzungen , Verfahren zur ihrer Herstellung und ihre Verwendung
WO2008104473A2 (en) * 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag Pyrazolopyriidine derivatives and their use as kinase inhibitors
EP1992344A1 (de) 2007-05-18 2008-11-19 Institut Curie P38 Alpha als therapeutisches Target für Erkrankungen, die mit einer FGFR3- Mutation assoziiert sind
US8080546B2 (en) 2007-10-26 2011-12-20 Amgen Inc. Pyrazolo-pyridinone derivatives and methods of use
EP2070929A1 (de) 2007-12-11 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Alkynylarylverbindungen und Salze davon, pharmazeutische Zusammensetzungen damit sowie Verfahren zu ihrer Herstellung und Verwendung
WO2009095752A1 (en) * 2008-01-29 2009-08-06 Glenmark Pharmaceuticals, S.A. Fused pyrazole derivatives as cannabinoid receptor modulators
WO2010093595A1 (en) 2009-02-10 2010-08-19 E. I. Du Pont De Nemours And Company Fungicidal 2-pyridones
WO2010111527A1 (en) * 2009-03-26 2010-09-30 Plexxikon, Inc. Pyrazolo [ 3, 4 -b] pyridines as kinase inhibitors and their medical use
PL2464232T3 (pl) 2009-08-10 2016-04-29 Samumed Llc Indazolowe inhibitory szlaku sygnałowego Wnt i ich zastosowania terapeutyczne
JP2013501792A (ja) * 2009-08-10 2013-01-17 サミュメッド リミテッド ライアビリティ カンパニー Ｗｎｔ／ｂ−カテニンシグナル伝達経路阻害剤としてのインダゾールおよびその治療的使用
EP2789615B1 (de) 2009-08-11 2017-05-03 Bristol-Myers Squibb Company Azaindazole als BTK-Kinasemodulatoren und Verwendung davon
FR2951172B1 (fr) * 2009-10-13 2014-09-26 Pf Medicament Derives pyrazolopyridines en tant qu'agent anticancereux
US8450340B2 (en) 2009-12-21 2013-05-28 Samumed, Llc 1H-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
US8673922B2 (en) 2010-07-15 2014-03-18 Bristol-Myers Squibb Company Azaindazole compounds
CN102617548A (zh) * 2011-01-31 2012-08-01 北京赛林泰医药技术有限公司 作为gpr受体激动剂的双环杂芳基化合物及其组合物和应用
MX2013009456A (es) * 2011-02-24 2013-12-12 Univ Hawaii Compuestos de azufre aromaticos sustituidos y metodos para su uso.
EP3473099A1 (de) 2011-09-14 2019-04-24 Samumed, LLC Indazol-3-carboxamide und deren verwendung als wnt/b-catenin-signalisierungsweghemmer
PH12017500997A1 (en) 2012-04-04 2018-02-19 Samumed Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
CN107417707A (zh) 2012-05-04 2017-12-01 萨穆梅德有限公司 1H‑吡唑并[3,4‑b]吡啶及其治疗应用
RU2495039C1 (ru) * 2012-07-31 2013-10-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Пермский государственный национальный исследовательский университет" МЕТИЛ 3-МЕТИЛ-5-[2-(4-АРИЛАМИНО)-2-ОКСОАЦЕТИЛ]-1,6-ДИФЕНИЛ-1Н-ПИРАЗОЛО[3,4-b]ПИРИДИН-4-КАРБОКСИЛАТЫ И МЕТИЛ 3-МЕТИЛ-5-[2-(4-АРИЛАМИНО)-2-ОКСОАЦЕТИЛ]-6-СТИРИЛ-1-ФЕНИЛ-1Н-ПИРАЗОЛО[3,4-b]ПИРИДИН-4-КАРБОКСИЛАТЫ И СПОСОБ ИХ ПОЛУЧЕНИЯ
WO2014110086A2 (en) 2013-01-08 2014-07-17 Samumed, Llc 3-(benzoimidazol-2-yl)-indazole inhibitors of the wnt signaling pathway and therapeutic uses thereof
CN104230922B (zh) * 2013-06-19 2016-12-28 中国科学院上海药物研究所 一类五元杂环并吡啶类化合物及其制备方法和用途
PT3409674T (pt) 2013-10-17 2022-07-18 Blueprint Medicines Corp Processo para preparar composições úteis para tratar distúrbios relacionados com kit
WO2016040180A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040188A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040190A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
WO2016040182A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine and therapeutic uses thereof
WO2016040181A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040184A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040193A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
WO2016040185A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof
WO2017023993A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-indol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017023972A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10206909B2 (en) 2015-08-03 2019-02-19 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017024003A1 (en) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017023988A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017023996A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
WO2017024026A1 (en) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-indol-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
WO2017024021A1 (en) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
US10206908B2 (en) 2015-08-03 2019-02-19 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
US10604512B2 (en) 2015-08-03 2020-03-31 Samumed, Llc 3-(1H-indol-2-yl)-1H-indazoles and therapeutic uses thereof
WO2017023980A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
US10519169B2 (en) 2015-08-03 2019-12-31 Samumed, Llc 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017023987A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
WO2017024015A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017023975A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
WO2017023989A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017024010A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
NZ742200A (en) 2015-11-06 2023-01-27 Samumed Llc Treatment of osteoarthritis
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
US20170275662A1 (en) * 2016-03-22 2017-09-28 The Quaker Oats Company Method and Apparatus for Controlled Hydrolysis
AR108325A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
SI3464285T1 (sl) 2016-06-01 2023-02-28 Biosplice Therapeutics, Inc. Postopek za pripravo N-(5-(3-(7-(3-fluorofenil)-3H-imidazo(4,5-C)piridin-2-il)-1H-indazol-5- il)piridin-3-il)-3-metilbutanamida
GB201611712D0 (en) 2016-07-02 2016-08-17 Hvivo Services Ltd Methods and compounds for the treatment or prevention of severe or persistent influenza
EP3528808B1 (de) 2016-10-21 2021-10-06 BioSplice Therapeutics, Inc. Verfahren zur verwendung von indazol-3-carboxamiden und deren verwendung als hemmer des wnt/b-catenin-signalwegs
KR102558716B1 (ko) 2016-11-07 2023-07-21 사뮤메드, 엘엘씨 단일-투여량, 즉시-사용가능한 주사용 제제
WO2018183712A1 (en) 2017-03-31 2018-10-04 Blueprint Medicines Corporation Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr
JOP20190278A1 (ar) 2017-05-31 2019-11-28 Novartis Ag مركبات 5، 6-ثنائية الحلقة مندمجة وتركيبات لعلاج الأمراض الطفيلية
JP2021501130A (ja) 2017-10-05 2021-01-14 フルクラム セラピューティクス，インコーポレイテッド ＤＵＸ４の発現を低減するためのｐ３８阻害剤の使用
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
GB201721793D0 (en) * 2017-12-22 2018-02-07 Hvivo Services Ltd Methods and compunds for the treatment or prevention of hypercytokinemia and severe influenza
SI3953357T1 (sl) 2019-04-12 2024-08-30 Blueprint Medicines Corporation Pirolotriazinski derivati za zdravljenje bolezni, posredovanih s KIT in PDGFRA
SMT202300447T1 (it) 2019-04-12 2024-01-10 Blueprint Medicines Corp Forme cristalline di (s)-1-(4-fluorofenil)-1-(2-(4-(6-(1-metil-1h-pirazol-4-yl)pirrolo[2,1-f][1,2,4]triazin-4-il)piperazinil)-pirimidin-5-il)etan-1-ammina e metodi di produzione
US11578071B2 (en) 2019-10-04 2023-02-14 University Of Kentucky Research Foundation Preparation of pyrazolo[3,4-B]pyridines as antimalarials
CN120529907A (zh) 2023-01-13 2025-08-22 普尔贝格制药(英国)有限公司 用于缓解癌症免疫疗法相关的细胞因子释放综合征的药物产品及方法
WO2025093869A1 (en) * 2023-11-01 2025-05-08 Poolbeg Pharma (UK) Limited P38 map kinase inhibitor for use in the treatment of inflammation

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3403158A (en) 1966-03-11 1968-09-24 Upjohn Co 1h-pyrazolo[3, 4-b]pyridines
US4264603A (en) * 1980-03-17 1981-04-28 Sterling Drug Inc. 5-(Pyridinyl)-1H-pyrazolo[3,4-b]pyridine-3-amines, their use as cardiotonics and their preparation
US4361568A (en) 1981-04-28 1982-11-30 Sterling Drug Inc. 5-(Pyridinyl)-1H-pyrazolo[3,4-b]pyridin-3-amines and their cardiotonic use
US4375467A (en) * 1981-09-28 1983-03-01 Sterling Drug Inc. 5-(Pyridinyl)-1H-pyrazolo[3,4-b] pyridines and their cardiotonic use
HUT74170A (en) 1993-07-06 1996-11-28 Pfizer Bicyclic tetrahydro pyrazolopyridines
ES2273369T3 (es) * 1996-08-28 2007-05-01 Pfizer Inc. Derivados 6,5 heterobiciclicos sustituidos.
ZA9811178B (en) 1997-12-13 2000-06-07 Bristol Myers Squibb Co Use of pyrazolo (3,4-b) pyridine as cyclin dependent kinase inhibitors.
US6559152B2 (en) * 1998-10-13 2003-05-06 Dupont Pharmaceuticals Company 6-substituted pyrazolo[3,4-d]pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
CN1263755C (zh) 1998-11-03 2006-07-12 葛兰素集团有限公司 作为选择性cox－2抑制剂的吡唑并吡啶衍生物
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
ES2254238T3 (es) 1999-10-27 2006-06-16 Novartis Ag Compuestos de tiazol e imidazo(4,5-b)piridina y su uso farmaceutico.
GB9929685D0 (en) 1999-12-15 2000-02-09 Merck Sharp & Dohme Therapeutic agents
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
ES2236217T3 (es) * 2000-04-25 2005-07-16 Bristol-Myers Squibb Company Uso de 5.tio.,sulfinil- y sulfonilpirazolo 3,4-b)-piridinas como inhibidores de la quinasa dependiente de la ciclina.
TR200402656T4 (tr) 2000-06-06 2004-11-22 Pfizer Products Inc. Antikanser ajanları olarak faydalı tiyofen türevleri
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
JP2004509891A (ja) 2000-09-22 2004-04-02 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー 抗糖尿病薬としてのピラゾロピリジンおよびピラゾロピリダジン
AR031176A1 (es) * 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
CN1630656A (zh) 2001-02-02 2005-06-22 三菱制药株式会社 二氢吡唑并吡啶化合物及其制药用途
PT1368355E (pt) * 2001-03-14 2006-09-29 Gruenenthal Gmbh Pirazolopirimidinas e tiazolopirimidinas substituidas, como analgesicos
GB0124848D0 (en) * 2001-10-16 2001-12-05 Celltech R&D Ltd Chemical compounds
WO2003068773A1 (en) 2002-02-12 2003-08-21 Glaxo Group Limited Pyrazolopyridine derivatives
BR0313396A (pt) 2002-08-12 2005-06-28 Sugen Inc 3-pirrolil-piridopirazóis e 3-pirrolil-indazóis, como inibidores de quinase
UA81790C2 (uk) 2002-12-19 2008-02-11 Фармация Италия С.П.А. Заміщені піролопіразольні похідні як інгібітори кінази
KR101312736B1 (ko) * 2003-02-27 2013-09-27 팔라우 파르마 에스에이 피라졸로피리딘 유도체
CN1809351A (zh) 2003-04-24 2006-07-26 麦克公司 Akt活性抑制剂
AR044129A1 (es) 2003-05-06 2005-08-24 Altana Pharma Ag Compuestos intermedios de imidazopiridina. proceso de preparacion.
WO2005028480A2 (en) * 2003-09-03 2005-03-31 Neurogen Corporation 5-aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds

Also Published As

Publication number Publication date
US20090286983A1 (en) 2009-11-19
ECSP056041A (es) 2006-01-27
HRP20050682A2 (en) 2006-05-31
EP1611131B1 (de) 2010-09-15
WO2004076450A8 (en) 2005-09-01
SI1611131T1 (sl) 2011-03-31
HRP20050682B1 (hr) 2014-09-12
US7468376B2 (en) 2008-12-23
KR101312736B1 (ko) 2013-09-27
NO20053647L (no) 2005-10-18
AR043416A1 (es) 2005-07-27
RU2359971C2 (ru) 2009-06-27
NO331917B1 (no) 2012-04-30
DE602004029145D1 (de) 2010-10-28
KR20060002782A (ko) 2006-01-09
AU2004215644A1 (en) 2004-09-10
JP2006519205A (ja) 2006-08-24
IL196021A (en) 2011-10-31
TWI325865B (en) 2010-06-11
PT1611131E (pt) 2010-12-20
PE20050521A1 (es) 2005-09-11
RS51768B (sr) 2011-12-31
ECSP12006041A (es) 2012-12-28
BRPI0407811A (pt) 2006-02-14
NO20053647D0 (no) 2005-07-27
NZ541836A (en) 2008-12-24
CA2515197C (en) 2011-10-18
RU2005130020A (ru) 2006-07-10
AU2004215644B2 (en) 2010-09-02
US20090005377A1 (en) 2009-01-01
IS7939A (is) 2005-07-14
UA81453C2 (en) 2008-01-10
TW200504061A (en) 2005-02-01
WO2004076450A1 (en) 2004-09-10
CY1111544T1 (el) 2015-08-05
IL196021A0 (en) 2009-02-11
EP1611131A1 (de) 2006-01-04
CA2515197A1 (en) 2004-09-10
MXPA05009069A (es) 2005-10-19
PL378296A1 (pl) 2006-03-20
RS20050609A (sr) 2007-12-31
JP4814783B2 (ja) 2011-11-16
DK1611131T3 (da) 2011-01-17
CL2004000398A1 (es) 2005-03-18
US20060167040A1 (en) 2006-07-27
IS2875B (is) 2014-04-15
HK1085214A1 (en) 2006-09-29
US8536194B2 (en) 2013-09-17

Similar Documents

Publication Publication Date Title
DK1611131T3 (da) Pyrazolopyridin-derivater
CY2014018I2 (el) Kαρβαμιδο - υποκατεστημενες πυραζολοπυριδινες
ATE340782T1 (de) Piperidinbenzolsulfonamidderivate
ATE352550T1 (de) Chinazolinderivate
ATE415400T1 (de) Pyrazolopyridinderivate
ATE420066T1 (de) Amidoacetonitrilderivate
ATE478870T1 (de) Spiroindolinpiperidinderivate
ATE460418T1 (de) Heterocyclocarboxamidderivate
ATE450506T1 (de) Indol-3-schwefelderivate
ATE467631T1 (de) Chinuclidinamidderivate
ATE438644T1 (de) Chinazolinderivate
DK2248807T3 (da) N-Phenyl-2-pyrimidinaminderivater
DK1606277T3 (da) Imidazol-4-yl-ethynyl-pyridinderivater
IS8180A (is) Nýjar besímídasólafleiður
ATE412651T1 (de) Pyrrolopyridinderivate
DE60307512D1 (de) 3h-chinazoline -4-on derivaten
DK1682129T3 (da) N-thiazol-2-ylbenzamidderivater
ATE423771T1 (de) Tetrahydrochinolinderivate
DK1706373T3 (da) Amidoacetonitrilderivater
IS8045A (is) Púrín-6-ón-afleiður
DE50306277D1 (de) 4-alkyl-/4-alkenyl-/4-alkinylmethyl/-1-arylcyclohexylamin-derivate
IS7991A (is) Setnar p-díamínóbensen afleiður
DE50311730D1 (de) Fredericamycin-derivate
ATE395327T1 (de) Amidoacetonitrilderivate

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1611131

Country of ref document: EP